{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["parsaclisib"]],"indication":"relapsed or refractory mantle cell lymphoma","name":"CITADEL-205","nct_id":"NCT03235544","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=citadel-205-nct03235544. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"(CITADEL-205)","arms":[{"description":"Participants received parsaclisib 20 mg tablets, orally, once daily (QD) for 8 weeks followed by 20 mg once weekly (QW) for up to 52 weeks.\n\nParticipants who were exposed to ibrutinib before enrollment were included in this group.","label":"Cohort 1: Treatment A (Exposed to Ibrutinib)","type":"EXPERIMENTAL"},{"description":"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 2.5 mg QD for up to 116 weeks.\n\nParticipants who were exposed to ibrutinib before enrollment were included in this group.","label":"Cohort 1: Treatment B (Exposed to Ibrutinib)","type":"EXPERIMENTAL"},{"description":"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 20 mg QW for up to approximately 145 weeks.\n\nParticipants who had not received a BTK inhibitor previously were included in this group.","label":"Cohort 2: Treatment A (Bruton's Tyrosine Kinase Inhibitor Naïve)","type":"EXPERIMENTAL"},{"description":"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 2.5 mg QD for up to approximately 136 weeks.\n\nParticipants who had not received a BTK inhibitor previously were included in this group.","label":"Cohort 2: Treatment B (Bruton's Tyrosine Kinase Inhibitor Naïve)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-04-30","type":"ACTUAL"},"conditions":["Lymphoma"],"enrollment":{"count":162,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Parsaclisib","otherNames":["INCB050465"],"type":"DRUG"}],"last_update":"2025-03-18","lead_sponsor":"Incyte Corporation","official_title":"A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-04-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"Up to 1016 days"}],"references":[],"start_date":{"date":"2017-11-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor","url":"https://clinicaltrials.gov/study/NCT03235544"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/citadel-205-nct03235544"}